[go: up one dir, main page]

AU6887996A - Method of reducing neurotoxic injury with zinc chelators - Google Patents

Method of reducing neurotoxic injury with zinc chelators

Info

Publication number
AU6887996A
AU6887996A AU68879/96A AU6887996A AU6887996A AU 6887996 A AU6887996 A AU 6887996A AU 68879/96 A AU68879/96 A AU 68879/96A AU 6887996 A AU6887996 A AU 6887996A AU 6887996 A AU6887996 A AU 6887996A
Authority
AU
Australia
Prior art keywords
neurotoxic injury
zinc chelators
reducing neurotoxic
reducing
chelators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68879/96A
Inventor
Dennis Wonkyu Choi
Jae-Young Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU6887996A publication Critical patent/AU6887996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU68879/96A 1995-09-01 1996-08-23 Method of reducing neurotoxic injury with zinc chelators Abandoned AU6887996A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US313495P 1995-09-01 1995-09-01
US003134 1995-09-01
US735695P 1995-11-20 1995-11-20
PCT/IB1996/000981 WO1997009976A2 (en) 1995-09-01 1996-08-23 Method of reducing neurotoxic injury with zinc chelators
US007356 1998-01-15

Publications (1)

Publication Number Publication Date
AU6887996A true AU6887996A (en) 1997-04-01

Family

ID=26671370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68879/96A Abandoned AU6887996A (en) 1995-09-01 1996-08-23 Method of reducing neurotoxic injury with zinc chelators

Country Status (2)

Country Link
AU (1) AU6887996A (en)
WO (1) WO1997009976A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834457A (en) * 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6407090B1 (en) 1999-06-23 2002-06-18 Zinc Therapeutics Canada, Inc. Zinc ionophores as anti-apoptotic agents
EP1463823B1 (en) * 2001-12-06 2013-03-06 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
IL151921A0 (en) * 2002-09-25 2003-04-10 Pharma Ltd D Liphopilic diesters of chelating agent for inhibition of enzyme activity
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
ES2533463T3 (en) 2006-10-12 2015-04-10 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20180071238A1 (en) * 2015-04-10 2018-03-15 Ohio University Compositions and Methods for Traumatized Tissues Using Zinc Chelators
WO2016179217A1 (en) * 2015-05-06 2016-11-10 Ohio University Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis
JP6958820B2 (en) 2015-12-14 2021-11-02 エックス4 ファーマシューティカルズ, インコーポレイテッド How to treat cancer
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7055380B2 (en) 2015-12-22 2022-04-18 エックス4 ファーマシューティカルズ, インコーポレイテッド Methods for treating immunodeficiency diseases
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN116554168B (en) 2016-06-21 2025-09-23 X4制药有限公司 CXCR4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932338A1 (en) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Treatment of Alzheimer's disease by chelating aluminium - using electron-rich oxine derivs., e.g. ester(s) or urethane(s) or 8-hydroxy-quinoline or -quinaldine
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
AU669493B2 (en) * 1991-11-12 1996-06-13 University Of Melbourne, The A method for assaying and treating Alzheimer's disease
GB9324871D0 (en) * 1993-12-03 1994-01-19 Lilly Industries Ltd Novel compounds
DE4431175A1 (en) * 1994-09-01 1996-04-11 Medico Pharma Vertriebs Gmbh New drugs containing chelating agents

Also Published As

Publication number Publication date
WO1997009976A3 (en) 1997-05-22
WO1997009976A2 (en) 1997-03-20

Similar Documents

Publication Publication Date Title
AU6887996A (en) Method of reducing neurotoxic injury with zinc chelators
AU3895595A (en) Methods of inhibiting conditions associated with neuropeptide
AU7379896A (en) Method and apparatus for improving the function of sensory cells
AU4918796A (en) Methods of treating or preventing psychiatric disorders
AU1322195A (en) Method of assay
AUPN271295A0 (en) Method of treatment
AU3969295A (en) Method of forming an absorbent article
AU6400294A (en) Tripterinin compound and method
AU1683395A (en) A method of treating glaucoma
AU3730093A (en) Methods of treating diabetes
PL313740A1 (en) Method of
AU1020997A (en) Method of treating sepsis
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU5001793A (en) Method of decreasing cutaneous senescence
AU1984195A (en) Masking method
HK1007981B (en) Method of punching parts
AU3861595A (en) A screw and method for the manufacturing and treatment of a screw
AU6973294A (en) Method for treatment of a piece
SG55119A1 (en) Spindle unit and method of asembling the spindle unit
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU7037994A (en) A method of galvanising
AU2348492A (en) Method of treating asthma
AU1006892A (en) Process for the electroextraction of zinc
AU2381295A (en) Method of treating allergic rhinitis
AU7349496A (en) Method for treatment of SLE